stress. 2 The degenerative changes occurring in the TMJ are linked with osteoclastogenesis, 3 however the molecular process associated with these changes remain unclear. It has been demonstrated that monocyte-macrophage derived cytokines levels are elevated in the synovial fluid of cases with TMD. 4 Studies reported that cytokines including interleukin [IL]-1beta [β], IL-6 may induce the release of proteinases and facilitate the expression of degrading enzymes and inflammatory mediators, leading to TMJ inflammation and bone and cartilage breakdown. 3 The tumor necrosis factor (TNF) is identified as a multifunctional pro-inflammatory cytokine that plays a role in various physiological processes as well as in pathological processes, such as inflammation, immunoregulation, proliferation, and apoptosis. The genes for TNF-α (OMIM 191160) and TNF-β (LT-α, MIM 153440), located within the major histocompatibility complex III region of chromosome 6, are closely linked with the genes for human leukocyte antigen (HLA) classes I (HLA-B) and II (HLA-DR). 5 TNF-β promotes cell apoptosis and inflammatory responses as it binds to TNF receptor type 1 and 2, respectively. TNF-β is produced by lymphocytes and it resembles TNF-α structurally. 5 These 2 substances bear 30% amino acid sequence similarity, have the same widely distributed corresponding cellular receptors and, thus share many of their functions. 5 The presence of functional single nucleotide polymorphisms (SNPs) within these genes, modulate their expression, for example -308 G/A SNP in the TNF-α and +252 A/G SNP in the TNF-β gene. In a recent study, chance of having the TNF-α -308 GA genotype was 2.87 fold higher in subjects with TMD compared to the control group. 6 SNP at position +252 within the first intron of TNF-β (transition guanine to adenine) (rs909253) that influences expression of both genes and plasma levels of TNF-α and TNF-β proteins. 7 The presence of G at this position determines the mutant allele which is less frequent allele and is associated with higher TNF-α and TNF-β production. 8 Changes in expression associated with polymorphic alleles of the TNF-β gene have been suggested in the pathogenic role of this cytokine in several chronic inflammatory and autoimmune disorders. Owing to relationship TMD and inflammation, we evaluated the association of TNF-β +252A/G variant with the risk to TMD in Turkish population. 9 TMD patients with any other autoimmune/inflammatory disease were excluded from the study. A detailed medical history was taken, followed by a complete oral examination. The subjects were interviewed using a standard questionnaire including demographics, duration of disease, family history, history of systemic disease, bruxism, chewing problems, sound in TMJ, TMJ blocking, pain severity, and clinical characteristics of pain. Pain intensity in patients was measured using the numeric pain rating scale (NPRS). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] A "numeric pain" score ranging from 0 (no pain) to 10 (maximum pain) was constructed. The
| MATERIAL S AND ME THODS

| Subjects
protocol of this study was approved by the Institutional Ethics
Committee, and all individuals gave written informed consent before entering the study.
| Genotyping
Blood samples were collected in ethylene diamine tetra-acetic acid (EDTA)-coated tubes from the patients with TMD and control subjects. Genomic DNA was isolated using commercial kit according to manufacturer protocol, and stored at −20°C until use. The TNF-β +252A/G variant was analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) assays. The segment was replicated using the following forward and reverse PCR primers: 5′-CCG TGC TTC GTG GTT TGG ACT-3′ and 5′-AGA GGG GTG GAT GCT TGG GTT C-3′, respectively. Then, the 782 bp PCR products were cut with NcoI restriction endonuclease at 37°C
overnight. The RFLP products were loaded on 3% agarose gels, stained with the ethidium bromide and monitorized on an ultraviolet transilluminator. While the product form A allele remained uncut, 2 fragments (586 and 196 bp) were observed for G allele.
| Statistical analysis
Analyses of data were performed using the Statistical Package Continuous data were given as mean ± standard deviation (SD).
Allele and genotype frequencies of patients and controls were compared with chi-square (χ 2 ) test. Odds ratio (OR) and 95% confidence interval (CI) were used for the assessment of risk factors. All P values were 2-tailed and P values < 0.05 were considered as significant. The Hardy-Weinberg Equilibrium (HWE) was evaluated by χ 2 test.
| RE SULTS
The demographical characteristics of the patients with TMD and controls are presented in Table 1 . Age and gender distributions were not different between patient and control groups (P > 0.05).
The genotype distribution and allele frequencies of TNF-β +252A/G variant in patients and control groups are presented in Table 2 . The genotype distribution of TNF-β +252A/G variant showed statistically significant difference between patients and controls, (P = 0.010). The patients had apparently higher frequencies in genotype AG of TNF-β +252 variant compared with the control group. There was statistically significant difference in the allele frequency of the TNF-β +252A/G variant between patients with TMD and the controls (P = 0.015, OR: 0.59, 95% CI:
0.39-0.89).
The individuals with TNF-β +252A/G G allele had an increased risk of developing TMD. Also, a more statistically significant association was observed when the patients were compared with the controls according to AA genotype vs AG+GG genotypes (P = 0.002, OR: 2.23, 95% CI: 1.31-3.82). There was no deviation from HWE for TNF-β +252A/G variant in both patient and control groups.
Furthermore, we also analyzed if any differences existed in clinical and demographical characteristics of patients according to genotype distribution. There was statistically significant difference between TNF-β +252A/G genotype distribution and chewing problems (P = 0.046) ( Table 3 ). The homozygous AA genotype frequency was higher in patients with chewing problems. parameters of pain such as pain severity, pain during sleep, chewing or speaking, pain localization, pain period, factors that trigger pain, pain type and pain duration. all articles reported that levels of pro-inflammatory cytokines were significantly higher in synovial fluid of TMD patients compared to in healthy control subjects. 16, 17 This finding suggests a proactive role of these cytokines in the pathogenesis of TMD and TMJ behaves similar to other synovial joints that are affected by osteoarthritis (OA) or rheumatoid arthritis (RA). It was found that cytokines like interleukin-1 beta (IL-1β), IL-6 and TNF-α may induce the release of proteinases and promote the expression of degrading enzymes and inflammatory mediators, ensuing TMJ inflammation and bone and cartilage degradation. 3, 4, 18, 19 In patients with chronic connective tissue disease involving-TMJ, TNF-α levels in TMJ synovial fluid were significantly elevated compared to plasma levels, suggesting the significant role of local cytokine production. 20 TNF-β is a cytokine that plays multiple roles in inflammatory and immunomodulatory processes. TNF-β is abundant in bone tissue and has been implicated as an important regulator of both bone formation and resorption which can stimulate osteoblastic proliferation and differentiation, as well as hinder mature osteoclasts and proliferation of mononuclear osteoclast precursors in vitro. 21 Previous studies have demonstrated that TNF-β levels are increased in the serum and synovial tissue of RA and OA patients. 22, 23 A recent report showed that TNF-β promotes proliferation and inflammatory cascade signaling in fibroblastlike synovities, which constitutes a trigger and onset point of RA. 24 Even at low levels, TNF-β is more likely to increase the secretion of IL-6, IL-8, and MMP3 compared to TNF-α. c-jun and c-fosheterodimer transcription factor family. 7 It was reported that TNF-β +252A/G variant is associated with various autoimmune disease including systemic lupus erythematosus, 26 Graves' disease, 27 systemic sclerosis, 28 and myasthenia gravis. 29 In addition, it was also reported that the TNF-β +252A/G G allele and GG genotype were correlated with breast cancer. 30, 31 Also, it was shown that GG genotype of TNF-β +252A/G variant was more common in RA patients compared to the controls. 32, 33 It was reported that there were significant differences in the percentages of alleles for TNF-β +252A/G between OA patients and the controls while there was not any significant difference in the genotypic distribution of TNFB +252A/G variant. 34 However, TNF-β +252 variant showed no significant difference in patients with ankylosing spondylitis compared to the controls.
| D ISCUSS I ON
In present study, we investigated whether TNF-β +252A/G variant is associated with TMD susceptibility in a Turkish population sample. In our study, TNF-β +252A/G variant AG genotype was significantly higher in patients (heterozygous advantage) compared to controls while AA genotype was significantly over-represented in controls compared to the patients (P = 0.010) ( Table 2) . A more statistically significant association was observed when the patients were compared with the controls according to AA genotype vs AG+GG genotypes (OR:2.23, 95% CI: 1.31-3.82; P = 0.002). There was a significant difference in the allele frequency of the +252 site of the TNF-β gene between TMD patients and controls (P = 0.012) ( Table 2 ). G allele, associated with a higher production of TNF-α and TNF-β, was found to be linked with a higher risk in development of TMD. Meanwhile, G allele of TNF-β +252A/G variant was associated with the increased risk of TMD. There was no deviation from HWE for TNF-β +252A/G variant in both patient and control groups. In addition, it was found that TNF-β +252A/G variant is associated with chewing problems (P = 0.046) (Table 3) . However, the presence of TNF-β +252A/G variation had no influence on the other clinical findings.
| CON CLUS ION
The report clearly showed that the TNF-β +252A/G variant are significantly associated with the susceptibility to TMD in Turks.
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